双歧杆菌四联活菌片对腹泻型肠易激综合征患者的短期疗效:可能由代谢而非多样性调控介导
一项在15家医院开展的随机双盲安慰剂对照多中心试验纳入290例腹泻型肠易激综合征患者,按1:1随机接受双歧杆菌四联活菌片或安慰剂治疗4周并随访2周。益生菌组应答率为67.59%,安慰剂组为36.55%(P<0.001)。益生菌未显著改变菌群多样性,但产短链脂肪酸菌丰度及粪便短链脂肪酸浓度升高。
要点
- 双歧杆菌四联活菌片治疗4周应答率67.59%,安慰剂组36.55%(P<0.001)。
- 腹痛评分较高的患者使用益生菌更可能应答(2.674[1.139-6.279])。
- 益生菌未显著改变菌群多样性,但产短链脂肪酸菌丰度及粪便短链脂肪酸浓度升高。
核心结论
- 双歧杆菌四联活菌片对腹泻型肠易激综合征具有显著短期疗效,且在腹痛评分较高的患者中更有效。
- 该益生菌可提高多种产短链脂肪酸菌的丰度及粪便短链脂肪酸浓度,与安慰剂相比。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心试验,在15家医院开展。
- 共290例符合入选标准的患者按1:1随机分配至益生菌组或安慰剂组,治疗4周并随访2周。
- 主要结局为应答率,定义为腹痛和腹泻同时改善的复合应答患者比例。
主要发现
- 连续给药4周后,益生菌组与安慰剂组应答率分别为67.59%和36.55%(P<0.001)。
- 益生菌组中腹痛评分较高者更可能应答(2.674[1.139-6.279])。
- 安慰剂组应答者汉密尔顿抑郁量表评分较低(0.162[0.060-0.439])、汉密尔顿焦虑量表评分较低(0.335[0.148-0.755])、腹胀程度较高(2.718[1.217-6.074])。
- 益生菌未显著改变菌群多样性,但丁酸菌属(Butyricimonas,P=0.048)、假丁酸弧菌属(Pseudobutyrivibrio,P=0.005)、巴恩斯氏菌属(Barnesiella,P=0.020)和萨特氏菌属(Sutterella,P=0.020)丰度增加。
- 粪便中丁酸(P=0.010)、戊酸(P=0.019)和己酸(P=0.046)浓度升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The therapeutic effect of probiotics for irritable bowel syndrome (IBS) was controversial. This study aims to evaluate the short-term efficacy of Bifidobacterium quadruple viable tablet in patients with diarrhea-predominant IBS and explore factors associated with response to probiotics. METHODS: A randomized, double-blind, placebo-controlled, multicenter trial was performed in 15 hospitals. A total of 290 patients who fulfilled the eligibility criteria were assigned to the probiotics or placebo group randomly with a ratio of 1:1 for a 4-week treatment and a 2-week follow-up. The primary outcome was the response rate. It was regarded as the proportion of patients with composite responses of improvement in both abdominal pain and diarrhea simultaneously. RESULTS: After 4-week continuous administration, the response rates of the probiotics and the placebo were 67.59% and 36.55%, respectively ( P < 0.001). In the probiotics, those with higher abdominal pain scores (2.674 [1.139-6.279]) were more likely to respond, but responders in placebo had lower Hamilton Depression Scale score (0.162 [0.060-0.439]), lower Hamilton Anxiety Scale score (0.335 [0.148-0.755]), and higher degree of bloating (2.718 [1.217-6.074]). Although the diversity of the microbiota was not significantly changed by probiotics, the abundance of bacteria producing short-chain fatty acids (SCFAs), including Butyricimonas ( P = 0.048), Pseudobutyrivibrio ( P = 0.005), Barnesiella ( P = 0.020), and Sutterella ( P = 0.020), and the concentration of SCFAs including butyric acid ( P = 0.010), valeric acid ( P = 0.019), and caproic acid ( P = 0.046) in feces increased. DISCUSSION: A Bifidobacterium quadruple viable tablet had a significant short-term efficacy for the treatment of diarrhea-predominant IBS and was more effective in patients with higher abdominal pain scores. This kind of probiotics could improve the abundance of several bacteria producing SCFAs and the concentration of fecal SCFAs compared with placebos.
引用
- Bai T, Xu Z, Xia P, et al. The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. Am J Gastroenterol. 2022. PMID: 36717369. doi:10.14309/ajg.0000000000002147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。